Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008917 | 0.91 | GSTP1 (0.48) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL5400224 | 0.91 | GSTP1 (0.48) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL4806962 | 0.89 | SLC6A2 (0.47) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL5013872 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL30239998 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL30239993 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL239121 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL15902840 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL30603836 | 0.81 | ESR1 (0.71) | GSTP1ESR1ESR2ALOX5HSD17B1 | |
| SCHEMBL31039575 | 0.78 | ESR1 (0.76) | GSTP1ESR1ESR2ALOX5HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192684-B2 | Polymerizable silicon-containing compound, manufacturing method, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| EP-0914333-B1 | PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040067436-A1 | Polymerizable silicon-containing compound, manufacturing method, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-0932618-B1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ASTRAZENECA AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| US-20030195158-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-0946589-B1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6541453-B2 | Amino acid sequences for use in the treatment of autoimmune or inflammatory diseases | SYNGENTA LIMITED (GB) | 2003-04-01 | — | — | US | disclosed |
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | disclosed |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2002-08-01 | — | — | US | disclosed |
| US-6355617-B1 | PEPTIDES, HYDROPHOBIC RESIDUES, AMINO ACIDS AND SEQUENCE | SYNGENTA LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946596-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195158-A1 | Peptide derivatives | HLA-DRB1, MICA, CD74 | GSTP1 1126/4885ESR1 4785/4885ESR2 2065/4885 |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | HLA-DRB1, MICA, TAP1 | GSTP1 1210/4885ESR1 4740/4885ESR2 3798/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | GSTP1 1245/4885ESR1 4134/4885ESR2 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.